Global Respiratory Disease Testing Market Size (2024 - 2029)

The respiratory disease testing market is projected to experience growth over the forecast period, driven by an increasing burden of respiratory diseases and advancements in testing technologies. The market's expansion is influenced by the demand for testing, which surged during the COVID-19 pandemic despite initial disruptions caused by lockdowns. Developments such as product launches and regulatory approvals are also contributing to market growth. However, the stringent regulatory framework for product approval may pose challenges to the market's expansion.

Market Size of Global Respiratory Disease Testing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Respiratory Disease Testing Market  Summary
Study Period 2019 - 2029
Market Size (2024) USD 5.80 Billion
Market Size (2029) USD 6.97 Billion
CAGR (2024 - 2029) 3.77 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Respiratory Disease Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Respiratory Disease Testing Market Analysis

The Global Respiratory Disease Testing Market size is estimated at USD 5.80 billion in 2024, and is expected to reach USD 6.97 billion by 2029, growing at a CAGR of 3.77% during the forecast period (2024-2029).

The studied market was hampered due to strict lockdowns and regulations by the government authorities at the beginning of the COVID-19 pandemic. The supply chain was disrupted due to this. The lockdowns imposed were followed by the cancellation of medical visits and disease diagnoses. This resulted in delays in respiratory testing and diagnostic procedures. However, the incidence of COVID-19 among respiratory patients increased. This created a demand for testing during the pandemic. According to the research article published in December 2021 by Respiratory Medicine and Research, patients with chronic respiratory diseases (CRD) were likely to experience respiratory symptoms from viral respiratory infections, including the SARS-CoV-2 infection, which can worsen the condition and necessitate hospitalization. However, the stabilizing cases of COVID-19 are expected to stabilize the growth of the market in the coming years. As per the weekly update by WHO in November 2021, after a 5-week drop, global COVID-19 cases stabilized last week, though deaths continued to decline. Cases were down in all but one of the six world regions, with the biggest drop in African countries (-35%). Thus, the COVID-19 pandemic had a considerable impact on the market.

Factors such as the growing burden of respiratory diseases and technological advancements in testing devices and modalities are expected to fuel the market growth over the forecast period.

Respiratory symptoms are among the leading causes of consultation with doctors and physicians in primary healthcare centers. Some of the major preventable chronic respiratory disorders are asthma, COPD, allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). The data updated by the CDC in September 2022 mentioned that 873,000 emergency department visits with COPD were reported in 2020 in the United States, and 5% of adults were diagnosed with COPD, emphysema, or chronic bronchitis for the first time. Thus, it shows the burden of the disease on society is expected to increase the demand for respiratory disease testing, which is expected to boost the growth of the market.

In addition, development activities such as product launches, approvals, acquisitions, and mergers, among other activities, are driving the overall market growth. For instance, in November 2021, Cipla Limited launched Spirofy, India's first pneumotach-based portable, wireless Spirometer, on World COPD Day. With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis in India. Such developments are anticipated to contribute to the market growth over the forecast period.

Therefore, due to the factors mentioned above, the studied market is anticipated to witness growth during the forecast period. However, the stringent regulatory framework for product approval is predicted to hinder the market growth.

Respiratory Disease Testing Industry Segmentation

As per the scope of the report, respiratory disease testing is used for the diagnosis of respiratory conditions in an individual. Some respiratory diseases include chronic obstructive pulmonary disease, asthma, and infections such as bacterial pneumonia and enterovirus respiratory virus. The respiratory disease testing market is segmented by Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests), End-user (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Test Type
Imaging Tests
Mechanical Tests
In-vitro Diagnostic Tests
By End User
Hospitals
Diagnostic Centres
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Respiratory Disease Testing Market Size Summary

The respiratory disease testing market is poised for growth, driven by the increasing prevalence of respiratory conditions and advancements in diagnostic technologies. The market experienced initial setbacks due to COVID-19-related lockdowns, which disrupted supply chains and delayed testing procedures. However, the pandemic also heightened the demand for respiratory testing, particularly among patients with chronic respiratory diseases. As COVID-19 cases stabilize, the market is expected to recover and expand, supported by technological innovations and the rising burden of respiratory diseases such as asthma, COPD, and tuberculosis. These factors are anticipated to boost the demand for testing and diagnostics, fostering market growth over the forecast period.

North America is a significant contributor to the market, with the United States leading due to high rates of COPD and other respiratory infections. The region's growth is further fueled by an aging population and increased focus on product innovation and development by major market players. The market is characterized by fragmentation, with key players engaging in mergers, acquisitions, and collaborations to enhance their market presence. Developments such as the launch of advanced diagnostic tools and point-of-care testing solutions are expected to drive segment growth. Despite the promising outlook, the market faces challenges from stringent regulatory frameworks, which may impact the pace of growth.

Explore More

Global Respiratory Disease Testing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Respiratory Diseases

      2. 1.2.2 Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Framework

    4. 1.4 Porter Five Forces

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Test Type

      1. 2.1.1 Imaging Tests

      2. 2.1.2 Mechanical Tests

      3. 2.1.3 In-vitro Diagnostic Tests

    2. 2.2 By End User

      1. 2.2.1 Hospitals

      2. 2.2.2 Diagnostic Centres

      3. 2.2.3 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Respiratory Disease Testing Market Size FAQs

The Global Respiratory Disease Testing Market size is expected to reach USD 5.80 billion in 2024 and grow at a CAGR of 3.77% to reach USD 6.97 billion by 2029.

In 2024, the Global Respiratory Disease Testing Market size is expected to reach USD 5.80 billion.

Respiratory Disease Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)